Transient oscillatory dynamics of interferon beta signaling in macrophages

BackgroundInterferon-beta (IFN-beta) activates the immune response through the type I IFN signaling pathway. IFN-beta is important in the response to pathogen infections and is used as a therapy for Multiple Sclerosis. The mechanisms of self-regulation and control of this pathway allow precise and environment-dependent response of the cells in different conditions. Here we analyzed type I IFN signaling in response to IFN-beta in the macrophage cell line RAW 264.7 by RT-PCR, ELISA and xMAP assays. The experimental results were interpreted by means of a theoretical model of the pathway.ResultsPhosphorylation of the STAT1 protein (pSTAT1) and mRNA levels of the pSTAT1 inhibitor SOCS1 displayed an attenuated oscillatory behavior after IFN-beta activation. In turn, mRNA levels of the interferon regulatory factor IRF1 grew rapidly in the first 50–90 minutes after stimulation until a maximum value, and started to decrease slowly around 200–250 min. The analysis of our kinetic model identified a significant role of the negative feedback from SOCS1 in driving the observed damped oscillatory dynamics, and of the positive feedback from IRF1 in increasing STAT1 basal levels. Our study shows that the system works as a biological damped relaxation oscillator based on a phosphorylation-dephosphorylation network centered on STAT1. Moreover, a bifurcation analysis identified translocation of pSTAT1 dimers to the nucleus as a critical step for regulating the dynamics of type I IFN pathway in the first steps, which may be important in defining the response to IFN-beta therapy.ConclusionsThe immunomodulatory effect of IFN-beta signaling in macrophages takes the form of transient oscillatory dynamics of the JAK-STAT pathway, whose specific relaxation properties determine the lifetime of the cellular response to the cytokine.

[1]  S. Markovic‐Plese,et al.  Regulation of Suppressors of Cytokine Signaling as a Therapeutic Approach in Autoimmune Diseases, with an Emphasis on Multiple Sclerosis , 2011, Journal of signal transduction.

[2]  E. Benveniste,et al.  Expression and Functional Significance of SOCS-1 and SOCS-3 in Astrocytes1 , 2008, The Journal of Immunology.

[3]  Satoru Shiono,et al.  Control mechanism of JAK/STAT signal transduction pathway , 2003, FEBS letters.

[4]  X. Montalban,et al.  A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis. , 2009, Brain : a journal of neurology.

[5]  C. Samuel,et al.  Antiviral Actions of Interferons , 2001, Clinical Microbiology Reviews.

[6]  Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.

[7]  P. Kuo,et al.  Osteopontin Induces Ubiquitin-Dependent Degradation of STAT1 in RAW264.7 Murine Macrophages1 , 2007, The Journal of Immunology.

[8]  Jordi Garcia-Ojalvo,et al.  Physical approaches to the dynamics of genetic circuits: a tutorial , 2011, 1105.4335.

[9]  S. Pellegrini,et al.  Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2. , 2007, The Biochemical journal.

[10]  D. Lucas,et al.  Analysis of the IFN-gamma-signaling pathway in macrophages at different stages of maturation. , 1998, Journal of immunology.

[11]  X. Montalban,et al.  Predicting responders to therapies for multiple sclerosis , 2009, Nature Reviews Neurology.

[12]  Tina Toni,et al.  Parameter inference and model selection in signaling pathway models. , 2009, Methods in molecular biology.

[13]  S. Goodbourn,et al.  Degradation of STAT1 and STAT2 by the V Proteins of Simian Virus 5 and Human Parainfluenza Virus Type 2, Respectively: Consequences for Virus Replication in the Presence of Alpha/Beta and Gamma Interferons , 2002, Journal of Virology.

[14]  A. Takaoka,et al.  Interferon signalling network in innate defence , 2006, Cellular microbiology.

[15]  E. Benveniste,et al.  IFN‐β‐induced SOCS‐1 negatively regulates CD40 gene expression in macrophages and microglia , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  J. Darnell,et al.  The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. , 1996, The EMBO journal.

[17]  T. Taniguchi,et al.  Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Takaho A. Endo,et al.  A new protein containing an SH2 domain that inhibits JAK kinases , 1997, Nature.

[19]  M. Bar‐eli,et al.  Delivery of interferon to intracellular pathways by encapsulation of interferon into multilamellar liposomes is independent of the status of interferon receptors. , 1994, Cytokine.

[20]  Olaf Wolkenhauer,et al.  Systems biology of JAK-STAT signalling in human malignancies. , 2011, Progress in biophysics and molecular biology.

[21]  S. Sealfon,et al.  Immune response modeling of interferon beta-pretreated influenza virus-infected human dendritic cells. , 2010, Biophysical journal.

[22]  J. Sepulcre,et al.  A Network Analysis of the Human T-Cell Activation Gene Network Identifies Jagged1 as a Therapeutic Target for Autoimmune Diseases , 2007, PloS one.

[23]  Bryan R. G. Williams,et al.  Interferon-inducible antiviral effectors , 2008, Nature Reviews Immunology.

[24]  D. Harrison,et al.  The JAK/STAT signaling pathway , 2004, Journal of Cell Science.

[25]  S. Vukusic,et al.  Clinical characteristics of responders to interferon therapy for relapsing MS , 2003, Neurology.

[26]  Marek Kimmel,et al.  Model-based analysis of interferon-beta induced signaling pathway , 2008, Bioinform..

[27]  Anton J. Enright,et al.  A logic-based diagram of signalling pathways central to macrophage activation , 2008, BMC Systems Biology.

[28]  D. Hilton,et al.  SOCS: suppressors of cytokine signalling. , 1998, The international journal of biochemistry & cell biology.

[29]  Kenneth A. Loparo,et al.  Complex systems biology approach to understanding coordination of JAK-STAT signaling , 2007, Biosyst..

[30]  Olaf Wolkenhauer,et al.  Mathematical modelling of interferon-gamma signalling in pancreatic stellate cells reflects and predicts the dynamics of STAT1 pathway activity. , 2010, Cellular signalling.

[31]  James W. Jacobberger,et al.  Major Differences in the Responses of Primary Human Leukocyte Subsets to IFN-β , 2010, The Journal of Immunology.

[32]  B. Oliver-Martos,et al.  Gene expression in IFNß signalling pathway differs between monocytes, CD4 and CD8 T cells from MS patients , 2011, Journal of Neuroimmunology.

[33]  S. Pellegrini,et al.  Comparable potency of IFNα2 and IFNβ on immediate JAK/STAT activation but differential down-regulation of IFNAR2 , 2007 .

[34]  X. Montalban,et al.  Clinical characteristics of responders to interferon therapy for relapsing MS , 2004, Neurology.

[35]  J. Hiscott,et al.  Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins , 1997, Oncogene.

[36]  H. Yokosawa,et al.  Degradation of transcription factor IRF-1 by the ubiquitin-proteasome pathway. The C-terminal region governs the protein stability. , 2000, European journal of biochemistry.

[37]  J. Timmer,et al.  Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  K Imada,et al.  The Jak-STAT pathway. , 2000, Molecular immunology.

[39]  B. Sherry,et al.  Basal Expression Levels of IFNAR and Jak-STAT Components Are Determinants of Cell-Type-Specific Differences in Cardiac Antiviral Responses , 2007, Journal of Virology.

[40]  A. Reder,et al.  Therapeutic role of beta-interferons in multiple sclerosis. , 2006, Pharmacology & therapeutics.

[41]  U. Vinkemeier,et al.  Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations , 2008, Proceedings of the National Academy of Sciences.

[42]  Li Lin,et al.  SOCS1 (suppressor of cytokine signaling 1) , 2011 .

[43]  Alexei A. Sharov,et al.  Database for mRNA Half-Life of 19 977 Genes Obtained by DNA Microarray Analysis of Pluripotent and Differentiating Mouse Embryonic Stem Cells , 2008, DNA research : an international journal for rapid publication of reports on genes and genomes.

[44]  George Stark,et al.  Isolation and Characterization of a Human STAT1Gene Regulatory Element , 2002, The Journal of Biological Chemistry.

[45]  G. Giovannoni,et al.  Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon. , 2012, CNS & neurological disorders drug targets.

[46]  T. Mak,et al.  Roles of interferon-regulatory factors in T-helper-cell differentiation , 2005, Nature Reviews Immunology.

[47]  Ana Rouzaut,et al.  Direct Effects of Type I Interferons on Cells of the Immune System , 2011, Clinical Cancer Research.

[48]  Yoh Iwasa,et al.  Robustness of the signal transduction system of the mammalian JAK/STAT pathway and dimerization steps. , 2006, Journal of theoretical biology.

[49]  C. Schindler,et al.  Suppressor of Cytokine Signaling (SOCS) 1 Inhibits Type I Interferon (IFN) Signaling via the Interferon α Receptor (IFNAR1)-associated Tyrosine Kinase Tyk2* , 2011, The Journal of Biological Chemistry.